Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
10 pending office actions • 7 art units • 10 examiners • 0 of 10 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Immatics Biotechnologies GmbH maintains a company patent portfolio in the Biotechnology & Pharmaceuticals technology area, currently featuring 10 pending office actions. These actions are distributed among 10 distinct examiners, which means that every pending matter is being handled by a different individual. This high degree of examiner diversity suggests a broad range of perspectives on the company's patent applications. The portfolio's prosecution is spread across 7 distinct art units.
OUSPENSKI, ILIA I is the busiest examiner for the portfolio, though this examiner is only responsible for 1 busiest examiner pending office action. This reflects the distribution of the 10 pending office actions across the 10 distinct examiners. The involvement of 7 distinct art units indicates that the company's biotechnology and pharmaceutical innovations are categorized into several specialized sub-fields at the patent office. OUSPENSKI, ILIA I is among the ten officials currently reviewing the company's work.
With 10 distinct examiners and 7 distinct art units, the prosecution strategy for Immatics Biotechnologies GmbH must be individualized for each application. There is no single examiner who holds significant influence over the portfolio's overall progress. Practitioners must navigate the specific tendencies of 10 different examiners across 7 different art units, requiring a versatile approach to the Biotechnology & Pharmaceuticals landscape. The 10 pending office actions represent a wide-reaching engagement with the patent office.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (10%) |
| §112 only | 3 (30%) |
| Double-patenting only | 1 (10%) |
| Double-patenting + other | 3 (30%) |
| No statute on record | 2 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OUSPENSKI, ILIA I | 1 | 77.5% | +20.4% |
| SANG, HONG | 1 | 55.0% | +62.4% |
| ESSEX, LAURA ANN | 1 | 60.5% | +35.2% |
| REDDIG, PETER J | 1 | 57.9% | +40.2% |
| CANELLA, KAREN A | 1 | 62.2% | +32.8% |
| SKELDING, ZACHARY S | 1 | 59.7% | +41.2% |
| YOUTCHOM PENDIE, EMMANUEL LED | 1 | 66.7% | +40.0% |
| MOSELEY II, NELSON B | 1 | 68.0% | +41.5% |
| FONTAINHAS, AURORA M | 1 | 37.9% | +49.2% |
| DUFFY, BRADLEY | 1 | 54.5% | +45.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18178055 | PERSONALIZED IMMUNOTHERAPY AGAINST SEVERAL NEURONAL AND BRAIN TUMORS | FONTAINHAS, AURORA M | 153d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18178055 | PERSONALIZED IMMUNOTHERAPY AGAINST SEVERAL NEURONAL AND BRAIN TUMORS | FONTAINHAS, AURORA M | 153d overdue |
| 18315183 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | MOSELEY II, NELSON B | 27d |
| 18323577 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS | YOUTCHOM PENDIE, EMMANUEL LED | 34d |
| 18647837 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | OUSPENSKI, ILIA I | — |
| 18533733 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST NON-SMALL CELL LUNG CANCER AND OTHER CANCERS | SANG, HONG | — |
| 18529656 | AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY NON-HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | ESSEX, LAURA ANN | — |
| 18505361 | METHODS OF IDENTIFYING METASTATIC LESIONS IN A PATIENT AND TREATING THEREOF | REDDIG, PETER J | — |
| 18345700 | PEPTIDES, COMBINATION OF PEPTIDES, AND CELL BASED MEDICAMENTS FOR USE IN IMMUNOTHERAPY AGAINST URINARY BLADDER CANCER AND OTHER CANCERS | CANELLA, KAREN A | — |
| Art Unit | Apps |
|---|---|
| 1649 | 1 |
| 1646 | 1 |
| 1644 | 1 |
| 1647 | 1 |
| 1642 | 1 |
| 1675 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18647837 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | OUSPENSKI, ILIA I | — | §112DP | Non-Final OA | — | Pending | Apr 26, 2024 |
| 18533733 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST NON-SMALL CELL LUNG CANCER AND OTHER CANCERS | SANG, HONG | — | §102§103§112DP | Non-Final OA | — | Pending | Dec 08, 2023 |
| 18529656 | AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY NON-HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | ESSEX, LAURA ANN | 1649 | §112Other | Non-Final OA | — | Pending | Dec 05, 2023 |
| 18505361 | METHODS OF IDENTIFYING METASTATIC LESIONS IN A PATIENT AND TREATING THEREOF | REDDIG, PETER J | 1646 | §103DP | Non-Final OA | — | Pending | Nov 09, 2023 |
| 18345700 | PEPTIDES, COMBINATION OF PEPTIDES, AND CELL BASED MEDICAMENTS FOR USE IN IMMUNOTHERAPY AGAINST URINARY BLADDER CANCER AND OTHER CANCERS | CANELLA, KAREN A | — | §112 | Non-Final OA | — | Pending | Jun 30, 2023 |
| 18343502 | TRANSFECTED T-CELLS AND T-CELL RECEPTORS FOR USE IN IMMUNOTHERAPY AGAINST CANCERS | SKELDING, ZACHARY S | 1644 | §112Other | Non-Final OA | — | Pending | Jun 28, 2023 |
| 18323577 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS CANCERS | YOUTCHOM PENDIE, EMMANUEL LED | 1647 | Other | Non-Final OA | 34d | Pending | May 25, 2023 |
| 18315183 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | MOSELEY II, NELSON B | 1642 | Other | Non-Final OA | 27d | Pending | May 10, 2023 |
| 18178055 | PERSONALIZED IMMUNOTHERAPY AGAINST SEVERAL NEURONAL AND BRAIN TUMORS | FONTAINHAS, AURORA M | 1675 | §101Other | Non-Final OA | 153d overdue | Pending | Mar 03, 2023 |
| 18052009 | RECRUITING AGENT FURTHER BINDING AN MHC MOLECULE | DUFFY, BRADLEY | 1643 | DP | Final Rejection | — | Pending | Nov 02, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial